Suppr超能文献

与高剂量玻璃体内注射曲安奈德相关的白内障进展的客观评估。

Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection.

作者信息

Chu Y K, Chung E J, Kwon O W, Lee J H, Koh H J

机构信息

Siloam Eye Hospital, Seoul, Korea.

出版信息

Eye (Lond). 2008 Jul;22(7):895-9. doi: 10.1038/sj.eye.6702802. Epub 2007 Apr 13.

Abstract

PURPOSE

To investigate the progression of cataract after a high dose (25 mg) intravitreal triamcinolone acetonide injection in patients with macular oedema secondary to diabetes and retinal vein occlusion.

METHODS

This prospective interventional case series study included 38 patients (76 eyes) with diabetic retinopathy or retinal vein occlusion diagnosed with clinical examination and fluorescein angiography. The patients were treated with 25 mg IVTA in their one eye with macular oedema and the fellow eyes served as a control. Patients were asked to return the next day and weekly for 1 month and monthly thereafter by 6 months post-operative. The progression of the cataract using photographic evaluation according to the Lens Opacities Classification System III was documented and statistical analysis was done using the Kaplan-Meier survival analysis and the log-rank test.

RESULTS

Among the 38 treated eyes, there was an increase of cataract degree by 1 grade at the end of 6 months in 10 patients. The types of progressed cataract were PSC in seven patients, cortical in six patients, and nuclear sclerosis in one patient. Six months after the injections, there was a significantly higher rate of progression of PSC (P=0.023, log-rank test) and cortical opacities (P=0.011) in the treated group while the progression of nuclear cataract was not significantly different between the treated eye and the control eye.

CONCLUSION

A high-dose (25 mg) intravitreal triamcinolone acetonide injection induces the progression of cortical and posterior subcapsular opacity in patients with diabetic macular oedema and retinal vein occlusion.

摘要

目的

研究高剂量(25毫克)玻璃体内注射曲安奈德对糖尿病继发黄斑水肿及视网膜静脉阻塞患者白内障进展的影响。

方法

本前瞻性干预性病例系列研究纳入了38例患者(76只眼),这些患者经临床检查和荧光素血管造影诊断为糖尿病视网膜病变或视网膜静脉阻塞。对其中一只眼患有黄斑水肿的患者,在其患眼内注射25毫克曲安奈德,对侧眼作为对照。要求患者术后次日复诊,术后1个月每周复诊,此后每月复诊直至术后6个月。根据晶状体混浊分级系统III,通过摄影评估记录白内障的进展情况,并使用Kaplan-Meier生存分析和对数秩检验进行统计分析。

结果

在38只接受治疗的眼中,1个月后白内障程度增加1级的患者有10例。进展性白内障的类型为后囊下混浊(PSC)7例,皮质混浊6例,核硬化1例。注射后6个月,治疗组PSC进展率(P=0.023,对数秩检验)和皮质混浊进展率(P=0.011)显著高于对照组,而治疗眼与对照眼的核性白内障进展无显著差异。

结论

高剂量(25毫克)玻璃体内注射曲安奈德可导致糖尿病黄斑水肿及视网膜静脉阻塞患者皮质混浊和后囊下混浊进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验